Latest Research Reports

PMDA approvals pivot to oncology

PMDA approvals pivot to oncology

Acute Myeloid Leukemia: noticeable differences in subtypes by age

Acute Myeloid Leukemia: noticeable differences in subtypes by age

A success story: the human papillomavirus vaccine

A success story: the human papillomavirus vaccine

Epidemiology of Heamophilia: a rare hereditary bleeding disorder

Epidemiology of Heamophilia: a rare hereditary bleeding disorder

CGRP Antagonists forecast to dominate migraine market by 2026

CGRP Antagonists forecast to dominate migraine market by 2026

AbbVie’s Humira sales continue to climb beyond its patent expiration

AbbVie’s Humira sales continue to climb beyond its patent expiration

Top ten selling products of atrial fibrillation

Top ten selling products of atrial fibrillation

Generic sales erosion in neurology: the bigger they are, the harder they fall

Generic sales erosion in neurology: the bigger they are, the harder they fall

Risk of Venous thromboembolism higher in ageing population

Risk of Venous thromboembolism higher in ageing population

The need for action: improving awareness and early diagnosis of SLE

The need for action: improving awareness and early diagnosis of SLE

Geographical variations in spondyloarthropathies prevalence related to HLA-B27 Prevalence

Geographical variations in spondyloarthropathies prevalence related to HLA-B27 Prevalence

Recent failures in Alzheimer’s Research and Development (R&D)

Recent failures in Alzheimer’s Research and Development (R&D)

Total Prevalent Cases of Dyslipidemia Expected to Grow Globally

Total Prevalent Cases of Dyslipidemia Expected to Grow Globally

C. difficile pipeline vaccines could offer an alternative to antibiotics

The incidence of Clostridium difficile has increased significantly over the last two decades, due in part to the emergence of new, hyper-virulent strains. In recent years it has surpassed MRSA...

C. difficile pipeline vaccines could offer an alternative to antibiotics

FDA approval of siliq for psoriasis – how will the drug perform in an already overcrowded market?

FDA approval of siliq for psoriasis – how will the drug perform in an already overcrowded market?

Development of PARP inhibitors for ovarian and breast cancer is equally extensive

A large number of clinical trials evaluating inhibitors of the enzyme poly ADP ribose polymerase (PARP) in breast and ovarian cancers are either ongoing or completed....

Development of PARP inhibitors for ovarian and breast cancer is equally extensive

Targeted therapies will radically improve head and neck cancer treatment

Head and neck cancer (HNC) is the sixth most common cancer worldwide, and the majority of available treatments are highly toxic...

Targeted therapies will radically improve head and neck cancer treatment

Amgen and Cytokinetics: moving forward with chronic heart failure therapy

In December, Amgen and Cytokinetics announced that they will be moving forward with their novel chronic heart failure (HF) therapy omecamtiv mecarbil (OM) with the launch of their Phase III...

Amgen and Cytokinetics: moving forward with chronic heart failure therapy

FDA approves Eucrisa, first-in-class PDE4 inhibitor for atopic dermatitis

On 14 December 2016, Pfizer announced the US Food and Drug Administration's (FDA) approval of Eucrisa (crisaborole) ointment 2%, a non-steroidal topical phosphodiesterase-4 (PDE4) inhibitor for...

FDA approves Eucrisa, first-in-class PDE4 inhibitor for atopic dermatitis